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Abstract
Objective: Matrix metalloproteinases (MMPs) and tissue inhibitors of matrix metalloproteinases (TIMPs) play a role in
neuroinflammation after brain trauma injury (TBI). Previous studies with small sample size have reported higher circulating
MMP-2 and MMP-9 levels in patients with TBI, but no association between those levels and mortality. Thus, the aim of this
study was to determine whether serum TIMP-1 and MMP-9 levels are associated with mortality in patients with severe TBI.
Methods: This was a multicenter, observational and prospective study carried out in six Spanish Intensive Care Units.
Patients with severe TBI defined as Glasgow Coma Scale (GCS) lower than 9 were included, while those with Injury Severity
Score (ISS) in non-cranial aspects higher than 9 were excluded. Serum levels of TIMP-1, MMP-9 and tumor necrosis factor
(TNF)-alpha, and plasma levels of tissue factor (TF) and plasminogen activator inhibitor (PAI)-1 plasma were measured in 100
patients with severe TBI at admission. Endpoint was 30-day mortality.
Results: Non-surviving TBI patients (n = 27) showed higher serum TIMP-1 levels than survivor ones (n = 73). We did not find
differences in MMP-9 serum levels. Logistic regression analysis showed that serum TIMP-1 levels were associated 30-day
mortality (OR = 1.01; 95% CI = 1.001–1.013; P = 0.03). Survival analysis showed that patients with serum TIMP-1 higher than
220 ng/mL presented increased 30-day mortality than patients with lower levels (Chi-square = 5.50; P= 0.02). The area under
the curve (AUC) for TIMP-1 as predictor of 30-day mortality was 0.73 (95% CI = 0.624–0.844; P,0.001). An association
between TIMP-1 levels and APACHE-II score, TNF- alpha and TF was found.
Conclusions: The most relevant and new findings of our study, the largest series reporting data on TIMP-1 and MMP-9 levels
in patients with severe TBI, were that serum TIMP-1 levels were associated with TBI mortality and could be used as a
prognostic biomarker of mortality in TBI patients.
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Introduction
Traumatic brain injury (TBI) is an important cause of disability,
mortality and cost [1]. Primary injury refers to the initial physical
forces applied to brain during the impact. Secondary injury occurs
over a period of hours or days following the initial traumatic
injury, and is developed by different mediators. During the
secondary injury there is an increase in the permeability of blood-
brain-barrier (BBB) and consequently appears brain edema [2–5].
Matrix metalloproteinases (MMPs) are a family of zinc-
containing endoproteinases implicated in degradation and remod-
elling of the extracellular matrix (ECM). They can be classified
broadly by substrate specificity into: collagenases (MMP-1, -8 and
-13), gelatinases (MMP-2 and -9), stromelysins (MMP-3, -10, -11),
PLOS ONE | www.plosone.org 1 April 2014 | Volume 9 | Issue 4 | e94370
elastases (MMP-7 and -12) and membranetype (MT-MMPs,
MMP-14, -15, -16 and -17). The regulation of its activity is
complex and occurs at several levels [6], such as transcriptional
(MMP gene expression in cells) that is influenced by numerous
stimulatory and suppressive factors that influence multiple
signalling pathways, as TNF-a, interleukin-1b, transforming
growth factor (TGF)-b, TGF-a; posttranscriptional (stability of
MMP transcripts in cells) that is influenced by glucocorticoids and
TGF-b; translational (release of MMP from cells) that is influenced
by plasmin and thrombin; and post-translational (activation of
MMPs after the release) that is influenced by oxidative stress,
nitrosidative stress, phosphorylation, proteolysis and tissue inhib-
itors of matrix metalloproteinases (TIMPs). We and others have
shown that MMPs have a role in normal physiological functions
such as the menstrual cycle, morphogenesis, tissue remodelling
and angiogenesis, and in diseases with abnormal ECM turnover,
such as arthritis, sepsis, tumour invasion, aneurysm formation and
atherosclerosis [7–11]. In addition, MMPs play a role in central
nervous system and are involved in the mechanisms associated
with neuroinflammation [12–14]. Several studies have inmunolo-
calized MMP in the human brain, specifically in astrocytes,
microglia and neurons [14]. The findings of several animal studies
suggested that MMP are involved in the disruption of the BBB,
edema formation and inflammation after central nervous system
trauma [15–17].
Previous studies with small sample size (fewer than 50 patients)
have reported higher circulating levels of MMP-2 and MMP-9 in
patients with TBI than in healthy control subjects [18–24]. Also
there has been found higher levels of MMP-2 and MMP-9 in brain
extracellular fluid (ECF), indicating that both local and systemic
trauma-induced upregulation of MMPs play an important role in
the pathophysiology of TBI [15,18]. However, an association
between MMP levels, severity and mortality of patients with TBI
was not reported. In a previous study by our team, we found
higher serum TIMP-1 and lower serum MMP-9 levels in non-
surviving than in surviving severe septic patients [9]. Thus, the
objective of this study was to determine whether serum levels of
TIMP-1 and MMP-9 are associated with severity and mortality of
patients with severe TBI.
Methods
Design and Subjects
This is a multicenter, observational, prospective study carried
out in 6 Intensive Care Units of Spain. The study was approved by
the Institutional Review Board of the 6 participant hospitals:
Hospital Universitario de Canarias (La Laguna, Santa Cruz de
Tenerife, Spain), Hospital Universitario Nuestra Sen˜ora de
Candelaria (Santa Cruz de Tenerife, Spain), Hospital General
de La Palma (La Palma, Spain), Hospital Clı´nico Universitario de
Valencia (Valencia, Spain), Hospital Insular (Las Palmas de Gran
Canaria, Spain), Hospital Universitario Dr. Negrı´n (Las Palmas de
Gran Canaria, Spain). The written informed consent from the
patients or from their legal guardians was obtained.
We included 100 patients with severe TBI. Severity of brain
trauma injury was classified according to Glasgow Coma Scale
(GCS) [25], and severe TBI was defined as GCS lower than 9
points.
Exclusion criteria were: age less than 18 years, pregnancy,
inflammatory or malignant disease and Injury Severity Score (ISS)
[26] in non-cranial aspects higher than 9 points.
Variables recorded
The following variables were recorded for each patient: sex, age,
ISS, GCS, lactic acid, platelets, international normalized ratio
(INR), activated partial thromboplastin time (aPTT), fibrinogen,
Acute Physiology and Chronic Health Evaluation II (APACHE II)
score [27] and brain lesion according to the Marshall computer
tomography (CT) classification [28].
End-point
The end-point was 30-day mortality.
Blood sample collection
Blood samples in 100 patients with severe TBI were collected in
the day of TBI to measure serum levels of TIMP-1 and MMP-9.
We also measured tumor necrosis factor (TNF)-alpha serum levels
to assess inflammation, and plasma levels of tissue factor (TF) to
assess coagulation and plasminogen activator inhibitor (PAI)-1 as a
fibrinolytic marker.
Determination of TIMP-1, MMP-9 and TNF-alpha serum
levels
Serum separator tubes were used to determine serum TIMP-1
and MMP-9 levels. Venous blood samples were taken and
centrifuged within 30 minutes at 1000 g for 15 min, and the
serum was removed and frozen at 280uC until measurement.
TIMP-1 and MMP-9 assays were performed at the Atheroscle-
rosis Research Laboratory of CIMA-University of Navarra
(Pamplona, Spain) and were assayed by specific ELISAs
(Quantikine, R&D Systems, Abingdon, United Kingdom) accord-
ing to the manufacturer’s instructions with a serum dilution of
1:100 and 1:80 respectively. This test has been validated by other
systems in serum samples [29]. The interassay coefficients of
variation (CV) were ,8% (n = 20) and detection limit for the
assays were 0.15 ng/mL and 0.31 ng/mL respectively.
TNF-alpha serum levels were measured in the Laboratory
Deparment of the Hospital Universitario de Canarias (La Laguna,
Santa Cruz de Tenerife, Spain) by a solid-phase, chemiluminis-
cents immunometrics assays kit (Immulite, Siemens Healthcare
Diagnostics Products, Llanberis, United Kingdom); and the
interassays coefficient of variation (CV) was ,6.5% (n = 20) and
detection limit for the assay was 1.7 pg/mL.
Determination of TF and PAI-1 plasma levels
Venous blood samples were collected in citrate collected plasma
tubes and centrifugedwithin 30 minutes at 1000*g for 15 min. The
plasma was removed and frozen at 280uC until measurement. TF
and PAI-1 assays were performed at the Laboratory Department
of the Hospital Universitario de Canarias (La Laguna, Santa Cruz
de Tenerife, Spain). TF levels were assayed by specific ELISA
(Imubind Tissue Factor ELISATM, American Diagnostica, Inc,
Stanford, CT, USA). PAI-1 antigen levels were assayed by specific
ELISA (Imubind Plasma PAI-1 ElisaTM, American Diagnostica,
Inc, Stanford, CT, USA). The interassay coefficients of variation
(CV) of TF and PAI-1 assays were ,8% (n = 20) and ,5%
(n = 20) respectively, and detection limits for the assays were
10 pg/mL and 1 ng/mL respectively.
Statistical Methods
Continuous variables are reported as medians and interquartile
ranges. Categorical variables are reported as frequencies and
percentages. Comparisons of continuous variables between groups
were carried out using Wilcoxon-Mann-Whitney test. Compari-
sons between groups on categorical variables were carried out with
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chi-square test. Multiple binomial logistic regression analysis was
applied to prediction of 30-day mortality. As number of events was
27 exitus, we constructed two multiple binomial logistic regression
models with only three predictor variables in each to avoid an over
fitting effect that may lead to choose a final model of order slightly
higher order than required [30]. In the first model were included
serum TIMP-1 levels, APACHE-II score and CT classification.
Previously to include the variable CT classification in the
regression analysis, it was recoded according with the risk of
death observed in the bivariated analysis as low (CT types 2 and 5)
and high risk (CT types 3, 4 and 6) of death. In the second model
were included serum TIMP-1 levels, GCS and age. Odds Ratio
and 95% confidence intervals were calculated as measurement of
the clinical impact of the predictor variables. Receiver operating
characteristic (ROC) analysis was carried out to determine the
goodness-of-fit of the of serum TIMP-1 levels to predict 30-day
mortality. Kaplan-Meier analysis of survival at 30 days and
comparisons by log-rank test were carried out using serum TIMP-
1 levels lower/higher than 220 ng/mL as the independent
variable and survival at 30 days as the dependent variable. The
association between continuous variables was carried out using
Spearmans rank correlation coefficient, and Bonferroni correction
was applied to control for the multiple testing problem. A P value
of less than 0.05 was considered statistically significant. Statistical
analyses were performed with SPSS 17.0 (SPSS Inc., Chicago, IL,
USA) and NCSS 2000 (Kaysville, Utah) and LogXact 4.1, (Cytel
Co., Cambridge, MA).
Table 1. Baseline clinical and biochemical characteristics of survivor and non-survivor patients.
Survivors (n =73) Non-survivors (n =27) P value
Gender female – n (%) 12 (16.4) 11 (40.7) 0.02
Age (years) - median (p 25-75) 47 (32–67) 66 (45–76) ,0.001
Computer tomography classification - n (%) 0.002
Type 1 0 0
Type 2 21 (28.8) 3 (11.1)
Type 3 13 (17.8) 5 (18.5)
Type 4 10 (13.7) 6 (22.2)
Type 5 26 (35.6) 5 (18.5)
Type 6 3 (4.1) 8 (29.6)
Temperature (uC) - median (p 25–75) 37. (35.6–37.3) 36.0 (35.0–37.0) 0.12
Sodium (mEq/L)- median (p 25–75) 139 (138–142) 141 (135–149) 0.19
Glycemia (g/dL) - median (p 25–75) 139 (120–163) 161 (142–189) 0.08
Leukocytes - median*103/mm3 (p 25–75) 14.7 (10.2–19.3) 18.3 (10.7–23.9) 0.46
PaO2 (mmHg) - median (p 25–75) 151 (116–217) 141 (104–186) 0.34
PaO2/FI02 ratio - median (p 25–75) 336 (242–407) 190 (154–316) 0.11
Bilirubin (mg/dl) - median (p 25–75) 0.50 (0.40–0.87) 0.75 (0.53–1.05) 0.045
Creatinine (mg/dl) - median (p 25–75) 0.80 (0.70–0.90) 0.95 (0.70–1.10) 0.44
Hemoglobin (g/dL) - median (p 25–75) 11.4 (10.4–13.0) 11.1 (9.4–12.3) 0.87
Glasgow Coma Scale score - median (p 25–75) 7 (6–8) 3 (3–6) ,0.00171
Lactic acid (mmol/L) median (p 25–75) 1.70 (1.23–2.50) 1.90 (1.15–4.55) 0.16
Platelets - median*103/mm3 (p 25–75) 182 (143–252) 215 (139–264) 0.48
INR - median (p 25–75) 1.03 (0.92–1.15) 1.22 (1.01–1.67) 0.15
aPTT (seconds) - median (p 25–75) 28 (25–32) 26 (25–31) 0.86
Fibrinogen (mg/dl) - median (p 25–75) 350 (282–444) 376 (246–560) 0.32
APACHE-II score - median (p 25–75) 19 (17–23) 26 (25–32) ,0.001
ISS - median (ppe 25–75) 25 (25–32) 25 (25–27) 0.24
ICP (mmHg) - median (p 25–75) 15 (14–20) 20 (12–30) 0.27
CPP (mmHg) - median (p 25–75) 68 (57–70) 60 (54–69) 0.46
TIMP-1 (ng/mL) - median (p 25–75) 219 (177–258) 302 (221–474) ,0.001
MMP-9 (ng/mL) - median (p 25–75) 760 (428–1113) 948 (357–1180) 0.62
TNF-alpha (pg/mL) - median (p 25–75) 9.72 (7.88–13.40) 13.65 (8.35–22.75) 0.12
Tissue Factor (pg/mL) - median (p 25–75) 189 (129–247) 194 (169–295) 0.18
PAI-1 (ng/mL) - median (p 25–75) 64 (32–89) 65 (39–99) 0.99
P 25–75 = percentile 25th–75th; PaO2 = pressure of arterial oxygen/fraction inspired oxygen; FIO2 = pressure of arterial oxygen/fraction inspired oxygen; ISS = Injury
Severity Score; INR = international normalized ratio; aPTT = activated partial thromboplastin time; APACHE II = Acute Physiology and Chronic Health Evaluation; ICP =
intracranial pressure; CPP = cerebral perfusion pressure; TIMP = tissue inhibitor of matrix metalloproteinase; MMP = matrix metalloproteinase; TNF = tumor necrosis
factor; PAI = plasminogen activator inhibitor
doi:10.1371/journal.pone.0094370.t001
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Results
Non-surviving TBI patients (n = 27) showed lower GCS, higher
age and female rate, and APACHE-II score than survivors
(n = 73). We found statistically significant differences in CT
classification between non-surviving and surviving patients. In
addition, non-surviving patients showed higher TIMP-1 levels
than surviving. There were not significant differences between
non-surviving and surviving patients in circulating levels of MMP-
9 and TNF-alpha, TF and PAI-1 (Table 1).
Multiple binomial logistic regression analysis showed that serum
TIMP-1 could predict 30-day mortality (OR = 1.01; 95%
CI = 1.001–1.013; P = 0.03) controlling for APACHE-II and CT
classification (Table 2). We found a mortality rate of 3/24 (12.5%)
in patients with CT classification type 2, 5/18 (27.8%) with type 3,
6/16 (37.5%) with type 4, 5/31 (16.1%) with type 5 and 8/11
(72.7%) with type 6. Previously to include the variable CT
classification in the regression analysis, it was recoded according
with the risk of death observed in the bivariated analysis as low
and high risk of death. As low risk of death were included patients
with CT classification types 2 and 5, with a mortality rate of 8/55
(14.5%). As high risk of death were included patients with CT
classification types 3, 4 and 6, with a mortality rate of 19/45
(42.2%).
Multiple binomial logistic regression analysis also showed that
serum TIMP-1 could predict 30- day mortality (OR = 1.01; 95%
CI = 1.003–1.015; P = 0.002) controlling for GCS and age
(Table 2).
Survival analysis showed that patients with serum TIMP-1
higher than 220 ng/mL presented higher 30-day mortality than
patients with lower levels (Chi-square: 5.50; P= 0.02) (Figure 1).
The area under the curve (AUC) for TIMP-1 as predictor of 30-
day mortality was 0.73 (95% CI = 0.624–0.844; P,0.001)
(Figure 2).
We found an association between TIMP-1 and APACHE-II
(rho = 0.33; P = 0.001), TF (rho = 0.43; P,0.001) and TNF-alpha
(rho = 0.43; P,0.001) (Table 3).
Discussion
To our knowledge, this study includes the largest series
reporting data on MMP levels in patients with severe TBI. The
most relevant and new findings of our study were the following: a)
non-surviving TBI patients had higher serum TIMP-1 levels than
Table 2. Multiple binomial logistic regression analysis of variables to predict 30-day mortality.
Variable Odds Ratio 95% Confidence Interval P
First Model
TIMP-1 levels 1.01 1.001–1.0127 0.03
APACHE-II score 1.31 1.147–1.499 ,0.001
Computer tomography classification (reference category: low risk of death) 7.65 1.976–29.616 0.003
Second Model
TIMP-1 levels 1.01 1.003–1.015 0.002
GCS score 0.57 0.403–0.798 0.001
Age 1.10 1.044–1.149 ,0.001
TIMP = tissue inhibitor of matrix metalloproteinase; APACHE II = Acute Physiology and Chronic Health Evaluation; GCS Glasgow Coma Scale
doi:10.1371/journal.pone.0094370.t002
Figure 1. Survival curves at 30 days using 220 ng/mL of TIMP-1
serum levels as cut-off.
doi:10.1371/journal.pone.0094370.g001
Figure 2. Receiver operation characteristic analysis using TIMP-
1 serum levels as predictor of mortality at 30 days.
doi:10.1371/journal.pone.0094370.g002
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surviving ones, b) there was an association between serum TIMP-1
levels and TBI severity and mortality, c) serum TIMP-1 levels
could be used as a prognostic biomarker of mortality in TBI
patients.
Previous studies with small sample size (fewer than 50 patients)
have reported higher circulating levels of MMP-2 and MMP-9 in
patients with TBI than in healthy control subjects [18–24].
However, they did not report differences in circulating MMP
levels between nonsurviving and surviving patients. We show, for
the first time, that non-surviving TBI patients showed higher
serum TIMP-1 levels than survivors at day 1; however, we did not
find significant differences in MMP-9 serum levels. Another new
finding of our study was the association between serum TIMP-1
levels and mortality in logistic regression analysis. Also, as
previously reported, we found that APACHE-II [31,32] and CT
classification [33] were associated with mortality. Interestingly, we
found for the first time that TIMP-1 levels could be used as
biomarker of mortality according to the ROC analysis. Another
new finding of our study was the association between TIMP-1
levels and TBI severity assessed by APACHE-II score.
The physiological role of higher TIMP-1 levels in non-survivors
compared to survivors TBI patients is still unknown. It is possible
that the increase in TIMP-1 levels in non-survivors may be a
consequence of increased MMP-2 and MMP-9 levels in non-
survivors during the initial phase of TBI in order to maintain the
balance between MMPs and TIMPs activity. However, we have
not determined MMP-2 levels to test this possible explanation and
we only found a trend, not statistically significant, of higher MMP-
9 levels in non-surviving than in surviving TBI patients. In one
study by Jaworski with TBI rats was found an increase of TIMP-1
mRNA expression in astrocytes and of TIMP-2 mRNA expression
in microglia and neurons, while the expression of TIMP-3 and
TIMP-4 was unaltered [34]. In one study by Tejima et al in TBI
mice was found lower MMP-9 levels and lower brain lesion
volumes in mice overexpressing TIMP-1 compared to wild-type
mice [35]. In some rodent models of brain injury, the treatment
with MMP-1 inhibitor has attenuated MMP-2 and MMP-9
activity, barrier disruption and edema formation [15–17].
MMPs play a role in the neuroinflammation [12–14]. During
the secondary injury there is an increase in the permeability of
BBB and consequently appears brain edema [2–5]. The findings of
several animal studies suggested that MMP are involved in the
disruption of the BBB and edema formation after central nervous
system trauma [15–17]. Interestingly, there has been reported that
circulating TIMP-1 levels are associated with brain edema in
ischemic stroke patients [36].
There has been described that coagulopathy after TBI is
frequent and represents a powerful predictor related to prognosis
[37–39]. This coagulopathy could present as hypo- and hyperco-
agulable state, and result in a variable degree of secondary injury
via subsequent ischemic and hemorrhagic lesioning. The proposed
underlying mechanisms may comprise the release of TF and
activation of hyperfibrinolysis. Interestingly, we found for the first
time an association between circulating TIMP-1 and TF levels.
However, we did not find significant differences between surviving
and non-surviving patients in coagulation data as platelet count,
INR, aPTT, fibrinogen and PAI-1. The association between
circulating TIMP-1 and TF levels could contribute in a
procoagulant state and thus, an increase of secondary injury via
subsequent ischemic lesioning.
TBI may result in a systemic inflammatory response syndrome
(SIRS) due to the synthesis and leaking to the circulation of pro-
inflammatory cytokines [40,41]. This SRIS may cause capillary
thrombosis, a single or multiple organ failure and, finally,
contribute to mortality. Interestingly, we found an association
between TIMP-1 and TNF-alpha levels; however, we did not find
differences between surviving and non-surviving patients in
TNFalpha levels. As previously mentioned, we also found an
association between TIMP-1 serum levels and TF plama levels,
and this may contribute to capillary thrombosis.
Taken together, these data suggest that TIMP-1 levels could
play a rol in pathophysiology of TBI. It is possible that increased
serum TIMP-1 levels in non-survivors TBI patients is not the
cause of death in TBI patients, but only a biomarker associated
with mortality.
From a therapeutic perspective, the development of modulators
of MMP activity could be used as a new class of drugs for the
treatment of patients with severe TBI for neuroprotection [15–17].
The strengths of our study are that it was a multicenter study
(which increases the external applicability of results to other
similar units) and the larger sample size in relation to previous
studies (that allowed us to increase the accuracy of the analysed
Table 3. Correlation between serum TIMP-1 levels and other baseline clinical and biochemical characteristics.
TIMP-1 (ng/mL)
APACHE-II score rho = 0.33; P = 0.001
GCS score rho =20.22; P = 0.03
Lactic acid (mmol/L) rho = 0.24; P = 0.02
TNF-alpha (pg/mL) rho = 0.53; P,0.001
Tissue Factor (pg/mL) rho = 0.43; P,0.001
PAI-1 (ng/mL) rho = 0.06; P = 0.71
Platelets (cells/mm3) rho =20.05; P = 0.61
INR rho = 0.10; P = 0.35
aPTT (seconds) rho = 0.08; P = 0.49
Fibrinogen (mg/dL) rho = 0.07; P = 0.59
MMP-9 (ng/mL) rho = 0.02; P = 0.88
TIMP = tissue inhibitor of matrix metalloproteinase; GCS = Glasgow Coma Scale; TNF = tumor necrosis factor; PAI = plasminogen activator inhibitor; INR =
international normalized ratio; aPTT = activated partial thromboplastin time; MMP = matrix metalloproteinase. Bonferroni correction to control the multiple testing
problem (0.05/11 = 0.004) was used. Only P-values lower than 0.004 were considered statistically significant.
doi:10.1371/journal.pone.0094370.t003
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parameters and report for the first time an association between
serum TIMP-1 levels and mortality). However, some limitations of
our study should be recognized. First, we did not perform the
analysis of other MMPs and TIMPs; and this could be interesting
to describe serum levels of other MMPs and TIMPs, and ratios
between them. Second, the measure of other inflammatory
cytokines would be desirable in order to better evaluate the
relationship between MMPs and inflammatory response in this set
of patients. Third, we did not report data about the evolution of
TIMPs and MMPs on the time to describe the evolution in non-
surviving and surviving TBI patients. Fourth, we have not
determined MMPs and TIMPs in cerebrospinal fluid (CSF) to
analyze whether there are an association between serum and CSF
levels. This could be interesting due to in a study by Grossetete et
al were found higher MMP-9 levels in CSF (but not in plasma),
higher MMP-2 in plasma (but not in CSF), and higher MMP-3
latent form in CSF (but not active form and neither in plasma) in
TBI patients compared to control subjects [22]. Fifth, the
determination of MMPs was carried out by ELISA, and could
be interesting to determine its active form by gelatine zymography
[42]. Sixth, the specificity of serum TIMP-1 levels to predict
mortality is low, and this restricts the application as biomarker to
discard survivor patients. Thus, additional studies are needed to
confirm the finding of our study.
Conclusions
The most relevant and new findings of our study, the largest
series reporting data on TIMP-1 and MMP-9 levels in patients
with severe TBI, were that serum TIMP-1 levels were associated
with TBI mortality and could be used as a prognostic biomarker of
mortality in TBI patients.
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